AbbVie, J&J blockbuster Imbruvica rakes in 11th FDA approval, as competitors work on eroding franchise

AbbVie and J&J’s market-leading Imbruvica, the original BTK inhibitor, continues to rake in approvals, while competition in the class of drugs heats up.

On Tuesday, the drug secured its 11th FDA approval. Imbruvica in combination with Roche’s rituximab has been sanctioned for use as the first line of defense in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).